摘要
目的探讨百令胶囊联合呼吸康复训练对矽肺合并慢阻肺患者IL-6水平及肺功能的影响。方法收集山东省医学科学院附属医院治疗的矽肺合并慢阻肺缓解期患者62例,按随机数字表法进行分组,对照组31例予以常规综合疗法治疗;研究组31例在综合治疗基础上予以百令胶囊联合呼吸康复训练治疗,治疗前后采血测定血气功能、肺功能、血清基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶组织抑制物-1(TIMP-1)及白介素(ILs)水平,同时对比临床生存质量变化状况。结果与对照组比较,研究组治疗后动脉血氧分压(Pa O2)、血氧饱和度(Sa O2)显著升高,动脉二氧化碳分压(Pa CO2)显著降低,治疗后一秒用力呼气容积(FEV1)、用力肺活量(FVC)、第1秒用力呼气容积占预计值的百分比(FEV1%pre)和第1秒用力呼气容积与用力肺活量比值(FEV1/FVC)显著升高,治疗后血清MMP-9、TIMP-1及IL-6、IL-8显著降低,差异均具有统计学意义(P<0.05);研究组治疗后生存质量状况显著优于对照组,差异具有统计学意义(P<0.05)。结论百令胶囊联合呼吸康复训练能显著降低矽肺合并慢阻肺患者IL-6水平,提高肺功能,效果显著。
Objective To investigate the effects of Bailing capsules combined with respiratory rehabilitation training on interleukin-6 level and lung function in the treatment of silicosis patients with COPD. Methods A total of 62 silicosis patients with COPD from our hospital were eoUected and randomly divided into experimental group and control group with 31 cases in each group. Patients in the control group were treated by conventional comprehensive therapy ; patients in the experimental group were treated on the basis of the control group with Bailing capsules combined with respiratory rehabilitation training, the blood gas function, lung function, serum MMP-9,TIMP-1 and ILs levels before and after treatment were determined, at the same time the clinical quality of life were compared. Results Compared with control group, the PaO2 and SaO2 levels of the experimental group after treatment were significantly increased, PaCO2 index was significantly decreased, the FEV1, FVC, FEV1% pre and FEV1 / b＂VC increased significantly, the serum MMP-9, TIMP-1, IL-6 and IL-8 after treatment significantly decreased, with statistical significance （ P 〈 0. 05 ） ; the quality of life of the experimental group was significant better than the control group after treatment, with statistical significance （ P 〈 0. 05 ）. Conclusion Bailing capsules combined with respiratory rehabilitation training in the treatment of COPD patients with silicosis could significantly reduce the IL-6 level, improve lung function, and the effect is remarkable.
出处
《中国生化药物杂志》
CAS
2016年第5期139-141,共3页
Chinese Journal of Biochemical Pharmaceutics
